Cargando…

The lytic activity of VSV-GP treatment dominates the therapeutic effects in a syngeneic model of lung cancer

BACKGROUND: Oncolytic virotherapy is thought to result in direct virus-induced lytic tumour killing and simultaneous activation of innate and tumour-specific adaptive immune responses. Using a chimeric vesicular stomatitis virus variant VSV-GP, we addressed the direct oncolytic effects and the role...

Descripción completa

Detalles Bibliográficos
Autores principales:	Schreiber, Liesa-Marie, Urbiola, Carles, Das, Krishna, Spiesschaert, Bart, Kimpel, Janine, Heinemann, Fabian, Stierstorfer, Birgit, Müller, Philipp, Petersson, Monika, Erlmann, Patrik, von Laer, Dorothee, Wollmann, Guido
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2019
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6889376/ https://www.ncbi.nlm.nih.gov/pubmed/31530903 http://dx.doi.org/10.1038/s41416-019-0574-7

Ejemplares similares

Oncolytic activity of the rhabdovirus VSV‐GP against prostate cancer
por: Urbiola, Carles, et al.
Publicado: (2018)

The Oncolytic Virus VSV-GP Is Effective against Malignant Melanoma
por: Kimpel, Janine, et al.
Publicado: (2018)

Application of interferon modulators to overcome partial resistance of human ovarian cancers to VSV-GP oncolytic viral therapy
por: Dold, Catherine, et al.
Publicado: (2016)

The Methyltransferase Region of Vesicular Stomatitis Virus L Polymerase Is a Target Site for Functional Intramolecular Insertion
por: Heilmann, Emmanuel, et al.
Publicado: (2019)

The viral vector vaccine VSV-GP boosts immune response upon repeated applications
por: Tober, R, et al.
Publicado: (2012)

Single-step rapid chromatographic purification and characterization of clinical stage oncolytic VSV-GP
por: Gautam, Saurabh, et al.
Publicado: (2022)

Heterologous Combination of VSV-GP and NYVAC Vectors Expressing HIV-1 Trimeric gp145 Env as Vaccination Strategy to Induce Balanced B and T Cell Immune Responses
por: Perdiguero, Beatriz, et al.
Publicado: (2019)

A modular self-adjuvanting cancer vaccine combined with an oncolytic vaccine induces potent antitumor immunity
por: Das, Krishna, et al.
Publicado: (2021)

Prediction and validation of murine MHC class I epitopes of the recombinant virus VSV-GP
por: Vijver, Saskia V., et al.
Publicado: (2023)

Neutralization Profile after Recovery from SARS-CoV-2 Omicron Infection
por: Rössler, Annika, et al.
Publicado: (2022)

Chemogenetic ON and OFF switches for RNA virus replication
por: Heilmann, E., et al.
Publicado: (2021)

Xenoantigen-Dependent Complement-Mediated Neutralization of Lymphocytic Choriomeningitis Virus Glycoprotein-Pseudotyped Vesicular Stomatitis Virus in Human Serum
por: Pipperger, Lisa, et al.
Publicado: (2019)

SARS-CoV-2 Omicron Variant Neutralization in Serum from Vaccinated and Convalescent Persons
por: Rössler, Annika, et al.
Publicado: (2022)

Can high COVID-19 vaccination rates in adults help protect unvaccinated children? Evidence from a unique mass vaccination campaign, Schwaz/Austria, March 2021
por: Winner, Hannes, et al.
Publicado: (2022)

Nonclinical pharmacokinetics and biodistribution of VSV-GP using methods to decouple input drug disposition and viral replication
por: Dambra, Richard, et al.
Publicado: (2022)

Oncolytic virotherapy enhances the efficacy of a cancer vaccine by modulating the tumor microenvironment
por: Koske, Iris, et al.
Publicado: (2019)

Heparan sulfate proteoglycans serve as alternative receptors for low affinity LCMV variants
por: Volland, André, et al.
Publicado: (2021)

A VSV-based assay quantifies coronavirus Mpro/3CLpro/Nsp5 main protease activity and chemical inhibition
por: Heilmann, Emmanuel, et al.
Publicado: (2022)

To B or Not to B: Mechanisms of Protection Conferred by rVSV-EBOV-GP and the Roles of Innate and Adaptive Immunity
por: Pinski, Amanda N., et al.
Publicado: (2020)

Comparison of Four SARS-CoV-2 Neutralization Assays
por: Riepler, Lydia, et al.
Publicado: (2020)

Differential infection of murine and human dendritic cell subsets by oncolytic vesicular stomatitis virus variants
por: Pipperger, Lisa, et al.
Publicado: (2021)

Impacts of rapid mass vaccination against SARS-CoV2 in an early variant of concern hotspot
por: Paetzold, Jörg, et al.
Publicado: (2022)

Regimen of Coronavirus Disease 2019 Vaccination Influences Extent and Kinetics of Antibody Avidity
por: Rössler, Annika, et al.
Publicado: (2022)

Reduced sensitivity of antibody tests after omicron infection
por: Rössler, Annika, et al.
Publicado: (2023)

Combining Oncolytic Viruses and Small Molecule Therapeutics: Mutual Benefits
por: Spiesschaert, Bart, et al.
Publicado: (2021)

Characterization of Immune Responses to SARS-CoV-2 and Other Human Pathogenic Coronaviruses Using a Multiplex Bead-Based Immunoassay
por: Borena, Wegene, et al.
Publicado: (2021)

Deep learning enables pathologist-like scoring of NASH models
por: Heinemann, Fabian, et al.
Publicado: (2019)

Mucosal Immunization of Cynomolgus Macaques with the VSVΔG/ZEBOVGP Vaccine Stimulates Strong Ebola GP-Specific Immune Responses
por: Qiu, Xiangguo, et al.
Publicado: (2009)

Immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccination in exposed and potentially exposed persons in the Democratic Republic of the Congo
por: Hoff, Nicole A., et al.
Publicado: (2022)

RSV Vaccine Based on Rhabdoviral Vector Protects after Single Immunization
por: Wilmschen, Sarah, et al.
Publicado: (2019)

Sprouty2 enhances the tumorigenic potential of glioblastoma cells
por: Park, Jong-Whi, et al.
Publicado: (2018)

Environmental Risk Assessment for rVSVΔG-ZEBOV-GP, a Genetically Modified Live Vaccine for Ebola Virus Disease
por: Tell, Joan G., et al.
Publicado: (2020)

Successful return to professional men’s football (soccer) competition after the COVID-19 shutdown: a cohort study in the German Bundesliga
por: Meyer, Tim, et al.
Publicado: (2021)

Prevalence of SARS-CoV-2 IgG antibodies in a large prospective cohort study of elite football players in Germany (May–June 2020): implications for a testing protocol in asymptomatic individuals and estimation of the rate of undetected cases
por: Mack, Dietrich, et al.
Publicado: (2021)

Deep neural network based histological scoring of lung fibrosis and inflammation in the mouse model system
por: Heinemann, Fabian, et al.
Publicado: (2018)

Marked Increase in Avidity of SARS-CoV-2 Antibodies 7–8 Months After Infection Is Not Diminished in Old Age
por: Pichler, Daniel, et al.
Publicado: (2021)

Six-Month Follow-Up of Immune Responses after a Rapid Mass Vaccination against SARS-CoV-2 with BNT162b2 in the District of Schwaz/Austria
por: Bánki, Zoltán, et al.
Publicado: (2022)

Characterizing SARS-CoV-2 neutralization profiles after bivalent boosting using antigenic cartography
por: Rössler, Annika, et al.
Publicado: (2023)

SARS-CoV-2 3CL(pro) mutations selected in a VSV-based system confer resistance to nirmatrelvir, ensitrelvir, and GC376
por: Heilmann, Emmanuel, et al.
Publicado: (2022)

Safety and immunogenicity of rVSVΔG-ZEBOV-GP Ebola vaccine in adults and children in Lambaréné, Gabon: A phase I randomised trial
por: Agnandji, Selidji T., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_igdmf5i4bk5sc7jeeg83r317b5